ISSN: 2309-5288 (Print)
ISSN: 2309-6152 (Online)
CODEN: JCLMC4

Journal of Coastal Life Medicine

Novel Hypertension Diagnosis Processes: A Review of Pharmacological Intervention & New Technologies in the Development of Hypertension Care

Received: 20 October 2022, **Revised:** 24 November 2022, **Accepted:** 28 December 2022

Kiran Mahajan1*, Mayuri Sawant2, Shubhrajit Mantry3, Shital Bidkar4, Ganesh Dama5

1,2,3,4,5 Department of Pharmaceutics SGMSPM's Sharadchandra Pawar College of Pharmacy, Dumbarwadi (Otur), Tal-Junnar, Dist- Pune, Maharashtra, India, 410504.

***Corresponding author: Dr. Kiran Mahajan**

Email: kirancmahajan@gmail.com

Key words:

Beta blocker, Inhibitors of angiotensin converting enzymes, Diuretic, Blockers of angiotensin II receptor, Self-management, Calcium channel blocker.

Abstract

A major source of trouble for cardiovascular complaints is hypertension. Around one-third of patients with hypertension are currently undiagnosed, and of those who are, about half do not use any antihypertensive medications. According to the World Health Organization (WHO), high blood pressure kills at least nine million people worldwide every year, either directly or indirectly. Many pharmacological guidelines for antihypertensive medications, along with their basic properties and modes of response are discussed. To be able to determine what kind of high blood pressure a certain pharmacological nobility using antihypertensive medicine are most appropriate for, the medium of movement is examined using a pharmacological technique. Moreover, pharmacological processes are used to characterize aspect concerns For a deeper understanding of their frequency & the circumstances where outpatient specifics are not recommended. Beta-blockers, diuretics, Angiotensin II receptor antagonists, RAAS inhibitors, & calcium channel blockers are the other five key pharmacological antihypertensive groups. In addition, it contains an analysis of how emerging technologies can facilitate the advanced hypertension identification and treatment, not just for the general public also however in specific demographic subgroups like older people, ladies who are expecting and those who have atrial fibrillation.

1. Introduction:

Hypertension a first- rate contributing element for cardiovascular complaint(CVD) and renal conditions, which can be troubles of comorbidities including myocardial infarction, stroke and coronary heart failure(HF)[1]. Studies have set up out that chance rudiments including weight problems and inheritable rudiments can affect the prevalence and enhancement of hypertension. In addition, complex nonsupervisory networks, inclusive of the RAAS, the alive device and arterial redoing, also have an effect on the development of high blood pressure[2]. Because blood pressure(BP) is tough to manipulate, the concern is locating medicine objects to rightly manipulate and control BP with inside the hypertensive populations[3]. In this review, we on the whole describe the classical and new medicine objects employed in high blood pressure remedy. Five primary pharmacological training of antihypertensive classes are certain then:

2. Beta Blockers:

The pharmacodynamic properties of beta-blockers, a diverse class of drugs, are influenced by their vasodilating characteristics, partial agonist exertion, and cardiac selectivity [4]. They all have similar effects on blood pressure lowering, although having varying degrees of input reduction and vasodilatation in line with their pharmacological components[1].

ISSN: 2309-5288 (Print)
ISSN: 2309-6152 (Online)
CODEN: JCLMC4
Journal of Coastal Life Medicine

Process of action:



Figure 1: MOA of beta blockers

Beta blockers function by inhibiting the effects of epinephrine, often known as adrenaline[5]. Beta blockers cause the heart to beat less vigorously and slowly, which reduces vital signs. Moreover, beta-blockers aid in widening roads and highways to improve blood flow[6,7].

Circle diuretics:

Bumetanide and furosemide are two of the most frequently used loop diuretics[9].

Process of action:



Figure 2: MOA of Loop Diuretics

The most effective diuretics for reducing ECF inflow and vital signs are loop diuretics. Furosemide, a type of circle diuretic, works by preventing the apical sodium, potassium, and chloride transporter from functioning within the thick pushing branch of the circle of Henle [10,11].

2.2. Thiazides:

The most used thiazide diuretics include hydrochlorothiazide, chlorthalidone, and indapamide [12].

ISSN: 2309-5288 (Print)
ISSN: 2309-6152 (Online)
CODEN: JCLMC4
Journal of Coastal Life Medicine

2.2.1. Process of action:



Figure 3: MOA of Thiazides

Thiazide use acutely increases urine flow, which reduces extracellular fluid (ECF) and plasma volume in addition to lowering sodium reabsorption. Reduced venous return, increased renin release, decreased flow, and lowered blood pressure are the results of this volume loss [13].

2.3 Sodium saving diuretics:

This course of drugs involves strong aldosterone antagonist like spironolactone and eplerenone as well as aldosterone-independent pills like amiloride and triamterene.

2.3.1 Process of action:



Figure 4: MOA of Potassium Sparing Diuretics

Amiloride and triamterene are examples of potassium-sparing diuretics that work to aid sodium reabsorption into the collecting tubule by either blocking aldosterone receptors or by acting as a list (spironolactone, eplerenone). This reduces hypokalemia by reducing water retention and excessive potassium output in the urine [14].

3. Inhibitors of Angiotensin Converting Enzymes:

ACE inhibitors are drugs that ease the tension in the veins and arteries, & lowers blood pressure[13].

ISSN: 2309-5288 (Print)
ISSN: 2309-6152 (Online)
CODEN: JCLMC4
Journal of Coastal Life Medicine

Process of action:



Figure 5: MOA of Angiotensin Converting Enzyme Inhibitors

Specifics that help to loosen up the modes and highways to lower blood pressure are known as ACE obstacles. An enzyme located inside the frame is prevented from producing the blood vessel-narrowing chemical angiotensin II by ACE inhibitors[14]. The coronary artery is forced by this narrowing, which might result in excessive blood pressure.

4. Blockers of Angiotensin Ii Receptor:

Valsartan, Telmisartan were quickly followed by losartan as the first blockers of angiotensin II receptor (ARB) available to lower blood pressure in the historical late 1990s [8].

Process of action:



Figure 6: MOA of blockers of angiotensin II receptor

Blockers of angiotensin II receptor aid in relaxing your blood vessels and heart muscles to lower increasing blood pressure and making it simpler for the heart to pump blood. Angiotensin may cause your blood vessels to constrict. This narrowing can exacerbate your significant signs and symptoms and force your heart to work harder [9,10,11].

ISSN: 2309-5288 (Print)
ISSN: 2309-6152 (Online)
CODEN: JCLMC4
Journal of Coastal Life Medicine

5. Calcium-Channel Blockers:

Dihydropyridines (DHPs), which include nifedipine and amlodipine blockers, of medications a course known as CCBs , which also include the benzothiazepine verapamil and the phenylalkylamine diltiazem [12,13].

Process of action:



Figure 7: MOA of CCB

The mechanism developed by CCB to stop calcium from entering the cells of the heart and arteries reduces blood pressure[14]. The coronary blood arteries and heart contract less powerfully when calcium is present. As a result of preventing calcium from entering, calcium channel blockers enable blood vessels to loosen and open[15,16].

6. Conclusion:

In this review complementary nature of the pharmacological training of the antihypertensive class found on assessment. By having in-depth knowledge of the molecular receptor targets, the numerous spots of movement alongside the arterial system, and the smaller arterial spots of movement, the researcher can determine which type of blood pressure a given pharmacological strength of antihypertensive medication is most indicated for and where inpatient classes are contraindicated. A strong pharmacokinetic profile with a high bioavailability, a long half-life, a known pharmacodynamic profile, and molecular target specificity must be combined, according to researchers. Despite significant support for treatment, studies show that many people's blood pressure levels are not well managed. The WHO has classified hypertension as one of the primary risk factors for morbidity and mortality on a global scale. In order to enhance the detection and management of high blood pressure in the population, new tactics, including new technologies, are needed. Contrary to the conventional cuff-based blood pressure measurement, the increasing use of smartphones and mobile health applications offers new prospects for the widespread monitoring of parameters similar to blood pressure, however verification of both delicacy and efficacy is currently absent.

ACKNOWLEDGEMENT

"We acknowledge the generous research infrastructure and supports from SPCOP College of Pharmacy, Otur, Pune, Maharashtra, India."

ISSN: 2309-5288 (Print)
ISSN: 2309-6152 (Online)
CODEN: JCLMC4
Journal of Coastal Life Medicine

CONFLICT OF INTEREST

None.

References:

[1] Suzanne1, Maria Czarina Acelajado2, George L. Bakris3, Dan R. Berlowitz4,5, Renata Cífková6, Anna F. Dominiczak7, Guido Grassi8,9, Jens Jordan10, Neil R. Poulter11, Anthony Rodgers12, and Paul K. Whelton13, HHS Public Access, Nat Rev Dis Primers; 4: 18014. doi:10.1038/nrdp.2018.14.

[2] Boutouyrie P, Achouba A, Trunet P, Laurent S; explor Trialist Group Amlodipine valsartan combination decreases central systolic blood pressure more effectively than the amlodipine-atenolol combination: the EXPLOR study. Hypertension. 2010; 55:1314-1322

[3] Frishman WH1, Alwar Shetty M. Beta-adrenergic blockers in systemic hypertension: pharmacokinetic considerations related to the current guidelines. Clin Pharmacokinetics. 2002; 41:505-516.

[4] Schiffrin EL. remodeling of resistance arteries in essential hypertension and effects of antihypertensive treatment. Am J Hypertension. 2004;17(12 Pt 1):1192-1200

[5] Danchin N, Laurent S. Coronary artery disease: Are β-blockers truly helpful in patients with CAD? Nat Rev Cardiol. 2012; 10:11-12.

[6] Little P, Barnett J, Barnsley L, Marjoram J, Fitzgerald-Barron A, Mant D. Comparison of acceptability of and preferences for different methods of measuring blood pressure in primary care. BMJ. 2002;325(7358):258–9.

[7] Boutouyrie P, Lacolley P, Briet M, Reignault V, Stanton A, Laurent S, Mahmud A. Pharmacological modulation of arterial stiffness. Drugs 2011; 71:1689-1701.

[8] Pratheek Sharma1, Harshit Beria1, Praveen Kumar Gupta1, Sumathra Manokaran1, A.H. Manjunatha Reddy1, Prevalence of hypertension and its associated risk factors, Journal of pharmaceutical science and research, 11(6), 2019, 2161-2167

[9] Qiannan Gaoa, Li Xuc, *, Jun Caia, b**, New drug targets for hypertension: A literature review, BBA-Molecular Basis of Disease 1867 (2021) 166037

[10] SAHBANATHUL MISSRIYA MA*, JOHNCEY JOHN, ASSESS THE PREVALENCE OF HYPERTENSION AND KNOWLEDGE REGARDING THE PREVENTION OF STROKE, Asian Journal of Pharmaceutical and Clinical Research, Vol 10, Issue 8, 2017, 177-180

[11] Laxmi Narayan Goit1*, Shaning Yang2, Treatment of Hypertension: A Review, Scientific research publishing, 2019, 3, 101-123

[12] Kotchen TA. Historical trends and milestones in hypertension research: a model of the process of translational research. Hypertension. 2011; 58:522-538.

[13] Williams GH, Burgess E, Kolloch RE, Ruilope LM, Niegowska J, Kipnes MS, Roniker B, Patrick JL, Krause SL. Efficacy of eplerenone versus enalapril as monotherapy in systemic hypertension. Am J Cardiol. 2004; 93:990-996.

[14] Brogden RN, Benfield P. Verapamil: a review of its pharmacological properties and therapeutic use in coronary artery disease. Drugs. 1996; 51:792-819

[15] Ong KT, Perdu J, De Backer J, Bozec E, Collignon P, Emmerich J, Fauret AL, Fiessinger JN, Germain DP, Georgesco G, Hulot JS, De Paepe A, Plauchu H, Jeunemaitre X, Laurent S, Boutouyrie P. Effect of celiprolol on prevention of cardiovascular events in vascular Ehlers-Danlos syndrome: a prospective randomised, open, blinded-endpoints trial. Lancet. 2010; 376:1476-1484.

[16] Welling PG. Pharmacokinetics of the thiazide diuretics. Biopharm Drug Dispos. 1986; 7:501-535.